Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J C, Leighton"'
Autor:
D W, Dexter, R K, Reddy, K G, Geles, S, Bansal, M A, Myint, A, Rogakto, J C, Leighton, L J, Goldstein
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(6)
To evaluate the clinical significance of drug resistance mechanisms in breast cancer, we examined the expression of MDR1 and MRP in primary breast carcinoma and normal adjacent tissue using a highly quantitative and reproducible reverse transcription
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6dcbacaefb0924c95dd03af5fdd9d634
https://pubmed.ncbi.nlm.nih.gov/9626474
https://pubmed.ncbi.nlm.nih.gov/9626474
Autor:
C J, Langer, J C, Leighton, R L, Comis, P J, O'Dwyer, C A, McAleer, C A, Bonjo, P F, Engstrom, S, Litwin, S, Johnson, R F, Ozols
Publikováno v:
Seminars in oncology. 22(4 Suppl 9)
A phase II trial of combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin included 54 chemotherapy-naive patients with advanced non-small cell lung cancer. Eligibility mandated Eastern Cooperative Oncology Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::93f68b8b0dae3108acaba3e1d4b46476
https://pubmed.ncbi.nlm.nih.gov/7544025
https://pubmed.ncbi.nlm.nih.gov/7544025
Autor:
J C, Leighton, L J, Goldstein
Publikováno v:
Hematology/oncology clinics of North America. 9(2)
Several potential mechanisms of chemotherapy resistance have been identified in adult solid tumors. The multidrug resistance (MDR) phenotype is one mechanism by which tumors may simultaneously develop resistance to multiple chemotherapeutic agents an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c0d043ec9b70d3d633f9bf13afb1b119
https://pubmed.ncbi.nlm.nih.gov/7642464
https://pubmed.ncbi.nlm.nih.gov/7642464
Autor:
M. J. Goldstein, A. Chapman, K. Sharan, J. C. Leighton, A. Muskett, J. Sansom, Edith P. Mitchell
Publikováno v:
Journal of Clinical Oncology. 24:13552-13552
13552 Background: Survival of patients with metastatic colorectal cancer (CRC) has increased with the advent of new chemotherapeutic and biologic agents. Yet, there remains a need for more effective third- and fourth-line chemotherapy. Thalidomide (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32035e7abad731a106d4dd382df4d947
https://doi.org/10.1200/jco.2006.24.18_suppl.13552
https://doi.org/10.1200/jco.2006.24.18_suppl.13552
Publikováno v:
Journal of Clinical Oncology. 23:3687-3687
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c4bc7443d93b008b01a992b9c92e495
https://doi.org/10.1200/jco.2005.23.16_suppl.3687
https://doi.org/10.1200/jco.2005.23.16_suppl.3687
Publikováno v:
Journal of Clinical Oncology. 22:7293-7293
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0938131bf764c1bbd6569ab7174e9ef
https://doi.org/10.1200/jco.2004.22.90140.7293
https://doi.org/10.1200/jco.2004.22.90140.7293
Publikováno v:
Journal of Clinical Oncology. 22:3184-3184
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::964104eb87a7798096ab8c65b264f3f6
https://doi.org/10.1200/jco.2004.22.90140.3184
https://doi.org/10.1200/jco.2004.22.90140.3184